CD33-targeted immunotherapy to help AML patients
Official title: Optimizing the Efficacy and Safety of CD33-Targeted Immunotherapy for Acute Myeloid Leukemia and Other CD33+ Disorders
Funded at Fred Hutchinson Cancer Center · NIH-11399862 · Data updated 2026-11-12
A patient-focused approach tests new antibody-drug strategies that target CD33 to improve safety and effectiveness for AML patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | August 15, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $161,878 |
| NIH project number | 5R50CA274319-04 |
| Project ID | NIH-11399862 on NIH RePORTER |
Who could benefit from this research
✓Could help
People with AML or related CD33-positive blood disorders who may later be eligible for CD33-targeted therapies.
✕Less likely to help
Patients with conditions not driven by CD33 or those unable to tolerate antibody-drug conjugates may not benefit.
What this research studies
This grant supports laboratory and preclinical work to optimize CD33-targeted therapies, including alpha-particle radioimmunotherapy with 211At, and aims to move promising strategies toward patient use. Researchers will test fully human antibodies against different parts of CD33 to improve how well the drugs kill cancer cells while reducing harm to normal blood cells. The work includes in vitro studies and animal models to understand mechanisms, safety, and potential clinical benefits. The ultimate goal is to create CD33 treatments that can be offered to patients who currently have limited options.
Why it matters
Potential benefit: If successful, this work could lead to more effective and safer CD33-targeted therapies for AML patients.
How similar studies have gone: Past CD33-directed treatments showed some benefit in select AML patients, but broader and safer responses are still being developed.
Where this research is happening
-
Fred Hutchinson Cancer Center
Seattle, United States Active
Researchers
- Principal investigator: Laszlo, George S — Fred Hutchinson Cancer Center
- Study coordinator: Laszlo, George S
Related research
Other NIH-funded projects on the same topics.
-
Myeloid-targeted oligonucleotide STAT3 blocker with TMLI for AML treatment
A new approach combines targeted radiation with a special gene-silencing treatment to help people with treatment-refractory acute myeloid leukemia.
-
Better CD33-targeted treatments for acute myeloid leukemia
Researchers are developing new CD33-targeted antibody therapies paired with a potent alpha-particle agent to help people with acute myeloid leukemia.
-
Improving treatment for acute myeloid leukemia with targeted radiation and immune therapy
This work explores a new way to treat acute myeloid leukemia that has been difficult to cure, by combining a special type of radiation with a targeted immune therapy.
-
Improving treatment for acute myeloid leukemia using targeted immunotherapy
This study is looking at new ways to make immunotherapy better and safer for people with acute myeloid leukemia (AML) by developing special antibodies that target a protein called CD33, and it aims to help improve treatment results while protecting healthy cells.
-
Targeting specific immune cells to improve treatment for acute myeloid leukemia
This study is testing a new way to treat acute myeloid leukemia (AML) by using a special combination of targeted treatments that block a protein called STAT3 along with a type of radiation therapy, to see if it can help improve survival for patients whose cancer hasn't responded to other treatments.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.